Global consensus sets a research agenda for young hips with primary cam morphology
Primary cam morphology sits at the center of a stubborn clinical problem: it is common in athletic populations, yet its downstream consequences remain uneven and poorly predicted. Some young people with the bony shape change develop pain, function loss, and eventually hip osteoarthritis, while others remain asymptomatic. The new Oxford consensus moves the field away from diffuse debate and toward a defined research agenda for conditions affecting the young person’s hip.
This was not a conventional clinical trial. It was a structured international consensus exercise built to decide what the field most urgently needs to study next, and it did so with an unusually broad panel. The Young Athlete’s Hip Research Collaborative brought together 65 panelists for the Delphi rounds, with 49, 44, and 42 participants contributing to the three ENHR ranking surveys, representing 18 countries and six stakeholder groups. A diverse panel matters here because the uncertainty is not limited to surgeons or sports physicians; it touches physiotherapy, rehabilitation, screening, diagnosis, and the long arc of prognosis.
One point became unmistakable: the field does not lack hypotheses. It lacks shared priorities.
Rehabilitation, prognosis, and load management rose to the top
The panel prioritized 18 of 38 research statements and organized them into seven domains. Three of those domains speak directly to bedside decision-making: best practice physiotherapy, rehabilitation progression and return to sport, and exercise intervention plus load management. These are the questions that matter when a teenager or young adult with hip symptoms wants to keep training, or when a clinician must decide whether symptoms should be managed conservatively, escalated, or observed.
The emphasis on rehabilitation is clinically sensible. In young athletes, symptoms often emerge in the context of repetitive hip flexion, rotation, and high joint loading, all of which can provoke pain in a joint already shaped by cam morphology. Yet rehabilitation protocols remain heterogeneous, and “return to sport” is often treated as a milestone rather than a biologically informed process. The consensus agenda places those gaps at the front of the queue, where they belong.
Load management deserves the same attention. If the bony morphology creates a predisposition to impingement, then training volume, intensity, movement patterns, and recovery may determine whether symptoms settle or spiral. Research in this area can clarify whether certain loading strategies reduce pain, preserve function, or delay deterioration in those at highest risk.
Diagnostic criteria remain inconsistent across studies and clinics
The panel also placed diagnostic criteria among the priority domains, a direct acknowledgment that the field still struggles with definition. Femoroacetabular impingement syndrome is not just a radiographic shape or a painful hip; it is a syndrome that depends on symptoms, clinical findings, and structural features. When those elements are applied inconsistently, research becomes difficult to compare and clinical thresholds become unreliable.
That definitional problem has practical consequences. Studies that mix asymptomatic morphology with symptomatic syndrome can blur prognostic signals, while screening programs without clear criteria risk both overdiagnosis and missed disease. A standardized framework would improve cohort selection, make longitudinal studies interpretable, and sharpen the evaluation of interventions. The consensus does not solve the diagnostic problem, but it identifies it as a core obstacle rather than a peripheral annoyance.
Prognosis and aetiology need stronger longitudinal evidence
Two of the seven domains focus on the natural history of disease: primary cam morphology prognosis and aetiology, and femoroacetabular impingement syndrome prognosis and aetiology. These are not abstract academic categories. They are the questions clinicians ask whenever they see an athlete with imaging abnormalities but uncertain symptoms: who will worsen, who will adapt, and who will progress to structural damage or osteoarthritis?
The need for better prognostic work is especially urgent because current uncertainty affects decisions made early in life. If clinicians could identify which morphology patterns, sports exposures, growth-related factors, or symptom trajectories are most likely to lead to harm, interventions could be targeted before irreversible joint disease appears. Equally, if some morphologies prove benign in most individuals, unnecessary restriction and medicalization could be avoided.
Aetiology is just as important. The consensus agenda implies that the field still lacks a clear account of why primary cam morphology develops in some young people and not others. That gap has obvious implications for prevention. It also influences how researchers interpret athlete-specific risk, skeletal maturation, and the interaction between training exposure and hip development.
Screening and the cost of uncertainty
Screening emerged as one of the priority areas, and for good reason. Screening strategies only make sense when the target condition, diagnostic threshold, and downstream pathway are clear. Without that clarity, screening can amplify noise, generate anxiety, and channel resources toward findings with uncertain clinical meaning.
The consensus does not endorse broad screening. It identifies screening as a research domain that needs better evidence before the field can know whether early detection helps, harms, or simply redistributes uncertainty. In young athletes, where asymptomatic morphology is common, the distinction between anatomical variation and disease is especially consequential. A screening program that cannot separate the two risks doing more harm than good.
Tension and dissent were treated as part of the method, not a problem to hide
The process did more than rank priorities. Panelists were also asked to surface areas of tension and dissent for immediate attention by the research community. That is a significant editorial choice in itself. Consensus exercises often smooth disagreement into a polished final product, yet unresolved conflict can be scientifically useful when it marks areas where evidence is thin, concepts are poorly defined, or patient values diverge.
By using an online two-round Delphi process, then ranking statements through the Essential National Health Research strategy, the collaborative built a transparent framework for deciding what should come first. Reporting followed REPRISE, strengthening the methodological credibility of the exercise. The result is a map of research needs that is both pragmatic and intentionally incomplete, because the field’s most difficult questions still require empirical study.
What this means for clinicians, funders, and researchers
For clinicians, the consensus reinforces that management of young people with hip pain and primary cam morphology cannot rely on imaging alone. For researchers, it narrows the field to questions that can meaningfully change care: how to structure physiotherapy, how to define and monitor rehabilitation progression, how to manage load, how to predict progression, how to define diagnosis, and whether screening has a valid place at all. For funders and policy-makers, the message is sharper still: investment should track the burden of disease and the uncertainty that most limits care.
The consensus is also a reminder that hip disease in the young is not a niche problem. It carries the possibility of lifelong pain, altered sport participation, and osteoarthritis in some patients. Research that can clarify which hips are at risk, which interventions help, and which screening strategies should be avoided has direct implications for disability prevention. The remaining challenge is not simply more studies, but better aligned studies that answer the questions the field has now agreed matter most.